دورية أكاديمية
Prevalence of Aflatoxin-Associated TP53R249S Mutation in Hepatocellular Carcinoma in Hispanics in South Texas.
| العنوان: | Prevalence of Aflatoxin-Associated TP53R249S Mutation in Hepatocellular Carcinoma in Hispanics in South Texas. |
|---|---|
| المؤلفون: | Jiao J; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Niu W; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wang Y; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Baggerly K; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ye Y; Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wu X; Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Davenport D; Doctor's Hospital at Renaissance, Edinburg, Texas.; University of Texas Rio Grande Valley School of Medicine, Edinburg, Texas., Almeda JL; Doctor's Hospital at Renaissance, Edinburg, Texas.; University of Texas Rio Grande Valley School of Medicine, Edinburg, Texas., Betancourt-Garcia MM; Doctor's Hospital at Renaissance, Edinburg, Texas., Forse RA; Doctor's Hospital at Renaissance, Edinburg, Texas.; University of Texas Rio Grande Valley School of Medicine, Edinburg, Texas., Stevenson HL; Department of Pathology, University of Texas Medical Branch, Galveston, Texas., Watt GP; School of Public Health, University of Texas Health Science Center at Houston, Brownsville Regional Campus, Brownsville, Texas., McCormick JB; School of Public Health, University of Texas Health Science Center at Houston, Brownsville Regional Campus, Brownsville, Texas., Fisher-Hoch SP; School of Public Health, University of Texas Health Science Center at Houston, Brownsville Regional Campus, Brownsville, Texas., Beretta L; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. lberetta@mdanderson.org. |
| المصدر: | Cancer prevention research (Philadelphia, Pa.) [Cancer Prev Res (Phila)] 2018 Feb; Vol. 11 (2), pp. 103-112. Date of Electronic Publication: 2017 Oct 31. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101479409 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1940-6215 (Electronic) Linking ISSN: 19406215 NLM ISO Abbreviation: Cancer Prev Res (Phila) Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Philadelphia, PA : American Association for Cancer Research |
| مواضيع طبية MeSH: | Mutation*, Aflatoxins/*administration & dosage , Carcinoma, Hepatocellular/*genetics , Gene Expression Regulation, Neoplastic/*drug effects , Hispanic or Latino/*genetics , Liver Neoplasms/*genetics , Tumor Suppressor Protein p53/*genetics, Adult ; Aged ; Aged, 80 and over ; Carcinoma, Hepatocellular/chemically induced ; Carcinoma, Hepatocellular/epidemiology ; Carcinoma, Hepatocellular/pathology ; Cell-Free Nucleic Acids ; Female ; Follow-Up Studies ; Humans ; Liver Neoplasms/chemically induced ; Liver Neoplasms/epidemiology ; Liver Neoplasms/pathology ; Male ; Middle Aged ; Poisons/administration & dosage ; Prevalence ; Prognosis ; Texas/epidemiology |
| مستخلص: | We aimed to determine whether aflatoxin dietary exposure plays a role in the high incidence of hepatocellular carcinoma (HCC) observed among Hispanics in South Texas. We measured TP53R249S somatic mutation, hallmark of aflatoxin etiology in HCC, using droplet digital PCR and RFLP. TP53R249S mutation was detected in 3 of 41 HCC tumors from Hispanics in South Texas (7.3%). We also measured TP53R249S mutation in plasma cell-free DNA (cfDNA) from 218 HCC patients and 96 Hispanic subjects with advanced fibrosis or cirrhosis, from South Texas. The mutation was detected only in Hispanic and Asian HCC patients, and patients harboring TP53R249S mutation were significantly younger and had a shorter overall survival. The mutation was not detected in any Hispanic subject with advanced fibrosis or cirrhosis. Genes involved in cell-cycle control of chromosomal replication and in BRCA1-dependent DNA damage response were enriched in HCCs with TP53R249S mutation. The E2F1 family members, E2F1 and E2F4, were identified as upstream regulators. TP53R249S mutation was detected in 5.7% to 7.3% of Hispanics with HCC in South Texas. This mutation was associated with a younger age and worse prognosis. TP53R249S was however not detected in Hispanics in South Texas with cirrhosis or advanced fibrosis. Aflatoxin exposure may contribute to a small number of HCCs in Hispanics in South Texas, but the detection of TP53R249S mutation in plasma cfDNA is not a promising biomarker of risk assessment for HCC in subjects with cirrhosis or advanced fibrosis in this population. Cancer Prev Res; 11(2); 103-12. ©2017 AACR . (©2017 American Association for Cancer Research.) |
| References: | Int J Cancer. 2015 Mar 1;136(5):E359-86. (PMID: 25220842) World J Gastroenterol. 2003 Apr;9(4):692-5. (PMID: 12679912) Nature. 1991 Apr 4;350(6317):427-8. (PMID: 1849234) Gastroenterology. 2011 Mar;140(3):1063-70. (PMID: 21094160) Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1638-43. (PMID: 19366907) IARC Monogr Eval Carcinog Risks Hum. 2002;82:1-556. (PMID: 12687954) Gene Expr Patterns. 2011 Mar-Apr;11(3-4):255-62. (PMID: 21216305) Genes Cells. 2008 Jul;13(7):667-78. (PMID: 18498355) Curr Drug Deliv. 2017;14 (2):272-281. (PMID: 27109336) Bioinformatics. 2009 May 1;25(9):1105-11. (PMID: 19289445) Carcinogenesis. 2010 Jan;31(1):71-82. (PMID: 19875698) J Anim Sci. 1992 Dec;70(12):3941-9. (PMID: 1474031) J Clin Oncol. 2014 Feb 20;32(6):579-86. (PMID: 24449238) Cancer Lett. 2013 Apr 30;331(1):46-51. (PMID: 23200676) Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9236-41. (PMID: 10430926) Hepat Res Treat. 2011;2011:697162. (PMID: 21760996) Oncogene. 2005 Sep 1;24(38):5858-67. (PMID: 16007211) PLoS One. 2013;8(2):e57043. (PMID: 23437305) Carcinogenesis. 1996 May;17(5):1007-12. (PMID: 8640905) Hepatol Res. 2000 May;17(2):102-111. (PMID: 10707004) Sci Signal. 2013 Apr 02;6(269):pl1. (PMID: 23550210) Clin Chem. 2017 Mar;63(3):691-699. (PMID: 28073896) Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):380-4. (PMID: 15734961) Cancer Lett. 2009 Dec 1;286(1):29-37. (PMID: 19376640) Asian Pac J Cancer Prev. 2013;14(12):7675-9. (PMID: 24460352) J Natl Cancer Inst. 2000 Jan 19;92(2):148-53. (PMID: 10639517) Carcinogenesis. 2010 Aug;31(8):1475-82. (PMID: 20538734) Mol Oncol. 2016 Dec;10 (10 ):1575-1584. (PMID: 28949453) J Racial Ethn Health Disparities. 2016 Mar;3(1):1-10. (PMID: 26896100) Cancer. 2016 May 1;122(9):1312-37. (PMID: 26959385) Sci Total Environ. 2010 Nov 1;408(23 ):6027-31. (PMID: 20870273) Clin Gastroenterol Hepatol. 2017 Aug;15(8):1311-1312. (PMID: 28344065) Nutr Cancer. 1999;35(1):27-33. (PMID: 10624703) BMC Cancer. 2009 Jun 26;9:204. (PMID: 19558663) Proc Natl Acad Sci U S A. 2002 May 14;99(10):6655-60. (PMID: 12011430) Cancer Res. 2001 Jan 1;61(1):33-5. (PMID: 11196182) JAMA. 2017 Jan 24;317(4):388-406. (PMID: 28118455) Cancer Discov. 2012 May;2(5):401-4. (PMID: 22588877) Gastroenterology. 2017 Mar;152(4):812-820.e5. (PMID: 27889576) Int J Cancer. 2004 Jun 20;110(3):374-9. (PMID: 15095302) J Exp Clin Cancer Res. 2013 Jan 11;32:3. (PMID: 23305119) Nat Rev Dis Primers. 2016 Apr 14;2:16018. (PMID: 27158749) Hepatol Res. 2016 Nov;46(12 ):1264-1274. (PMID: 26885668) Nat Rev Cancer. 2009 Oct;9(10):738-48. (PMID: 19776743) Lancet. 2015 Aug 22;386(9995):743-800. (PMID: 26063472) PLoS One. 2016 Mar 07;11(3):e0150978. (PMID: 26950933) J Clin Invest. 2017 Mar 1;127(3):830-842. (PMID: 28134624) Carcinogenesis. 2012 Jun;33(6):1219-24. (PMID: 22759751) |
| معلومات مُعتمدة: | P30 CA016672 United States CA NCI NIH HHS; R01 CA120719 United States CA NCI NIH HHS; R01 CA195524 United States CA NCI NIH HHS |
| المشرفين على المادة: | 0 (Aflatoxins) 0 (Cell-Free Nucleic Acids) 0 (Poisons) 0 (TP53 protein, human) 0 (Tumor Suppressor Protein p53) |
| تواريخ الأحداث: | Date Created: 20171102 Date Completed: 20190308 Latest Revision: 20211204 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC5811406 |
| DOI: | 10.1158/1940-6207.CAPR-17-0235-AT |
| PMID: | 29089331 |
| قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!